Spots Global Cancer Trial Database for primary peritoneal high grade serous adenocarcinoma

Every month we try and update this database with for primary peritoneal high grade serous adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02839707	Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT03586661	Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Copanlisib Niraparib	18 Years -	M.D. Anderson Cancer Center
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	NCT03943173	BRCA-Mutated Ov... BRCA1 Gene Muta... BRCA2 Gene Muta... High Grade Fall... High Grade Ovar... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Chemotherapy Olaparib Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02659241	Advanced Fallop... Advanced Ovaria... Advanced Primar... Carcinomatosis Fallopian Tube ... Ovarian High Gr... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Adavosertib Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	NCT05276973	Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Primary Periton... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Unresectable Fa... Unresectable Fa... Unresectable Ov... Unresectable Ov... Unresectable Pr... Unresectable Pr...	Biopsy Carboplatin Ipatasertib Paclitaxel	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	NCT02834013	Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom...	Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02756130	High Grade Fall... High Grade Ovar... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Birinapant Carboplatin Laboratory Biom... Pharmacological...	18 Years -	Jonsson Comprehensive Cancer Center
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	NCT03943173	BRCA-Mutated Ov... BRCA1 Gene Muta... BRCA2 Gene Muta... High Grade Fall... High Grade Ovar... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Chemotherapy Olaparib Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	NCT04034927	Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian High Gr... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Tremelimumab	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03587311	Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton...	Anetumab Ravtan... Bevacizumab Paclitaxel	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: